After widespread criticism from healthcare providers, drug companies, and lawmakers, CMS has announced that it will not go forward with its proposed Medicare Part B payment program. The experimental reimbursement model was intended to reduce outpatient drug spending, but oncologists worried it would have unfairly slashed their Part B payments.
After widespread criticism from healthcare providers, drug companies, and lawmakers, CMS has announced that it will not go forward with its proposed Medicare Part B payment program. The experimental reimbursement model was intended to reduce outpatient drug spending, but oncologists worried it would have unfairly slashed their Part B payments.
Under current Part B reimbursement rules, providers receive payments of an additional 6% of the sale price of a drug administered by infusion or injection. The proposed 5-year mandatory initiative, which was developed by the Center for Medicare and Medicaid Innovation at CMS, would have cut the extra payment to 2.5% of the drug’s average sale price plus a flat payment of $16.80 per drug per day.
The proposed changes were supposed to control drug spending by incentivizing physicians to choose less expensive drugs, but practitioners in some specialties said the new model was not feasible for them. In particular, oncologists raised concerns that they would be reimbursed much less for the expensive cancer treatments they provide. CMS acknowledged in the proposed rule that payments to medical oncologists would decline by 0.7% while increasing by 1.3% across the board for all specialties.
The decision by CMS not to implement the model came after the proposed rule provoked vastly negative public comments and pressure from lawmakers, including House Minority Leader Nancy Pelosi. In a statement, Pelosi said she and colleagues were “pleased” with the decision to cancel the proposal, a sentiment echoed by a number of patient advocacy groups.
“Cancer patients and their providers across the country can breathe a sigh of relief now that the Part B experiment on cancer care is finally dead,” said Ted Okon, executive director of the Community Oncology Alliance, in a statement. “It was encouraging to have such strong support from Congress to end this proposed model that was, at best, an overreach by CMS, created with no stakeholder input.”
The American Medical Association was also heartened by the announced reversal. In a statement, president Andrew W. Gurman, MD, said the group was “grateful that CMS came to the right decision after listening to stakeholders.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More